Our group focuses on the design, development, and utilization of molecular imaging agents based on single photon – and positron – emitting radionuclides. We combine the sensitivity of radionuclide imaging techniques with molecules engineered to identify certain types of cells or cell processes. Following the development of imaging probes and their use in cell-based assays, in vivo studies are performed using small animal single-photon emission computed tomography (SPECT) combined with x-ray CT. In addition, our laboratory is also interested in the development of therapeutic radiopharmaceuticals with novel molecular targets. Imaging- and therapeutic- agents for prostate cancer and breast cancer are currently under development. Other areas of interest include cell-trafficking / immunotherapeutics.